ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
Genflow Biosciences implements internal modifications to better align with its objectives in the US
Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
ValiRx PLC (AIM:VAL) Operational Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for
ValiRx PLC (AIM:VAL) Launch of Broker Offer to raise a maximum of £500,000
Launch of Broker Offer to raise a maximum of £500,000
ValiRx PLC (AIM:VAL) Quarterly Operational and Strategy Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
Poolbeg Pharma PLC (AIM:POLB) POLB 001 US Patent update
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
ValiRx PLC (AIM:VAL) Live Shareholder Q&A and industry events
Live Q&A: London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, invites shareholders to join the CEO, Suzy Dilly and
ValiRx PLC (AIM:VAL) Successful evaluation of breast cancer programme
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce that the project subject to the Evaluation
Genflow Biosciences (LON:GENF) Research Agreement Signed with Magnitude Biosciences Limited
Genflow (LSE: GENF) is pleased to announce it has entered into a research agreement with Magnitude Biosciences Limited (“Magnitude”), a UK-based, specialist biotechnology research organisation that supports drug discovery and
ValiRx PLC (AIM:VAL) Update on VAL201 sub-license agreement
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today providing an update on its proposed sub-license agreement with
Genflow Biosciences (LON:GENF) International patent application
Patent portfolio strengthened with international patent application under the Patent Cooperation Treaty